North America Point of Care Diagnostics Market 2025-2035: Comprehensive Insights by Type, Application, Technology & Key Players
The North America point of care diagnostics market is rapidly advancing, driven by the increased need for rapid, accessible, and accurate diagnostic tools across healthcare settings. Covering categories ranging from glucose monitoring kits and cardiac markers to molecular diagnostics and microfluidics, this market continues to expand as hospitals, clinics, and home care settings emphasize early diagnosis and patient-centric care. With significant investment in R&D and integration of advanced technologies, the market's growth trajectory is influenced by evolving disease prevalence, consumer demand for home healthcare, and innovations brought forward by top companies.
Latest Market Dynamics
Key Drivers
- Rising prevalence of chronic diseases, such as diabetes and cardiovascular disorders, is fuelling demand for point-of-care testing. For example, Abbott Laboratories’ recent expansions in their glucose monitoring platforms cater to the growing diabetic population.
- Increasing adoption of rapid diagnostics in home care and retail settings, driven by consumer preference for convenience and immediate results, is boosting the market. Companies like QuidelOrtho Corporation have launched over-the-counter infectious disease tests that meet this need.
Key Trends
- Integration of digital health platforms to facilitate data transfer and remote monitoring is on the rise. Siemens Healthineers has recently incorporated cloud-based connectivity within its POCT devices to streamline real-time results sharing.
- Expansion of multiplex testing platforms that enable simultaneous detection of multiple conditions is gaining traction. F. Hoffmann-La Roche Ltd advanced this trend with their cobas® Liat® system, which can diagnose multiple pathogens from a single sample.
Key Opportunities
- Expanding access to point-of-care testing in underserved and rural regions presents significant growth potential, particularly through public-private partnerships. Danaher Corporation’s recent community outreach programs highlight this approach.
- Development of novel biomarkers and miniaturized biosensors for early disease detection offers companies a pathway to differentiate and capture emerging segments. BD (Becton, Dickinson and Company) is investing in microfluidic-based POCT for early cancer screening.
Key Challenges
- Ensuring regulatory compliance and maintaining accuracy in decentralized settings can be a challenge for manufacturers and providers. Nova Biomedical continues to work closely with the FDA to streamline regulatory pathways for their POCT devices.
- Market fragmentation, with the presence of numerous small and medium manufacturers, often leads to inconsistencies in product quality. Trinity Biotech strives to standardize POCT offerings across North America to address this challenge.
Key Restraints
- High initial costs associated with the development and deployment of advanced POCT technologies may restrict adoption in cost-sensitive settings. Instrumentation Laboratory (Werfen) is seeking to reduce entry barriers by offering flexible finance schemes.
- Data security and patient privacy concerns with connected POCT devices may hinder the uptake of digital solutions. Roche is reinforcing cybersecurity frameworks within its POCT solutions to mitigate risks and enhance user trust.
North America Point of Care Diagnostics Market Share (%), By Type, 2025
In 2025, glucose monitoring kits and infectious disease tests collectively dominate the North American point of care diagnostics landscape. Glucose monitoring kits account for the largest market share, reflecting the impact of rising diabetes prevalence and a shift toward personalized chronic disease management. Infectious disease POCT maintains robust demand due to persistent public health concerns and the need for rapid outbreak response. Cardiac markers, pregnancy & fertility testing, and cholesterol test strips round out the major segments, benefiting from advances in assay sensitivity and consumer access. Innovation and convenience remain key factors shaping each segment’s performance.
North America Point of Care Diagnostics Market Share (%), By Applications, 2025
Diabetes and infectious disease applications remain at the forefront of point of care diagnostics adoption in North America for 2025. Diabetes commands the largest single share, driven by consumer uptake of self-monitoring solutions and an aging population. Infectious disease testing follows closely, with a pronounced need for rapid virus, bacteria, and pathogen identification in ambulatory and emergency care. Cardiology, oncology, and drug abuse testing continue to show incremental growth as POCT capabilities expand, allowing clinicians to react swiftly to a diverse range of urgent healthcare needs.
North America Point of Care Diagnostics Market Revenue (USD Million), 2020-2035
The North America point of care diagnostics market exhibits consistent growth from 2020 through 2035. In 2025, total market revenue is projected to reach 7,350 Million, up from 5,800 Million in 2021, with a sustained CAGR through the forecast period. Growth is underpinned by accelerating adoption of POCT in both clinical and non-clinical settings, improved accessibility, and continuous innovation by leading players. The forecast suggests that by 2035, revenue will surpass 15,200 Million as penetration into home and retail healthcare accelerates alongside advancements in digital health integration.
North America Point of Care Diagnostics Market Year-on-Year (%) Growth, 2020-2035
Year-on-year growth in the North America point of care diagnostics market is robust, averaging 6.5% annually between 2020 and 2025, driven by increased demand for rapid testing solutions during and after the pandemic. Growth rates peak around 2027 before gradually moderating as the market matures and product adoption stabilizes, yet ongoing product launches and technological upgrades sustain a healthy YOY trajectory through 2035.
North America Point of Care Diagnostics Market Share (%), By Region, 2025
The United States dominates the regional breakdown with nearly three-quarters of the North America point of care diagnostics market share in 2025, reflecting its advanced healthcare infrastructure, greater healthcare expenditure, and substantial investment in innovation. Canada secures a moderate share, driven by ongoing modernization of healthcare services, while Mexico’s market shows accelerating growth driven by increasing health awareness and expanding access to diagnostics, albeit from a smaller base.
North America Point of Care Diagnostics Market Share (%), By Key Players, 2025
Market competition is led by a handful of prominent companies, with Abbott Laboratories commanding a notable share through extensive POCT portfolios and global reach. F. Hoffmann-La Roche Ltd, Siemens Healthineers, and BD (Becton, Dickinson and Company) follow, each leveraging their innovation pipelines and established customer bases. Other players including QuidelOrtho Corporation and Danaher Corporation continue to gain momentum with strategic product launches and targeted acquisitions.
North America Point of Care Diagnostics Market Share (%), By Buyers, 2025
Hospitals represent the primary buyers in the North America POCT market, accounting for nearly half of all procurement volumes. Home care and retail pharmacies follow as growing distribution channels due to rising preference for decentralized testing. Diagnostic centers, clinics, and other buyers collectively continue to expand their roles, reflecting a diversified end-user landscape that reflects ongoing shifts in patient care models.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 7350 |
| Regions | US, Canada, Mexico |
| Segments | By Type, By Application, By Distribution Channels, By Technology, By Organization Size |
| Players | Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers, Danaher Corporation, BD, bioMérieux SA, QuidelOrtho Corporation, Sekisui Diagnostics, Chembio Diagnostics Inc., Trividia Health Inc., Instrumentation Laboratory (Werfen), Nova Biomedical, Trinity Biotech, OraSure Technologies Inc., Others |
Key Recent Developments
- July 2024: Abbott Laboratories launched a next-generation rapid molecular flu and COVID-19 combo test for home use, receiving FDA approval.
- June 2024: Siemens Healthineers introduced a cloud-connected POCT platform enabling real-time reporting for outpatient clinics across the US.
- August 2024: BD and Microsoft announced a strategic partnership to enhance cybersecurity features in all new connected POCT devices.
- September 2024: Roche expanded its cobas® Liat® molecular diagnostics range with a new multiplex assay for respiratory illnesses.
- July 2024: Danaher Corporation launched a public health initiative providing affordable POCT kits to rural health networks in Canada.
